ASCO 2012 LC Highlights: Dr. Joel Neal on the MEK Inhibitor Selumetinib in KRAS Mutation-Positive NSCLC (audio)

GRACEcast Lung Cancer Audio

English - September 11, 2012 03:56 - 5 minutes - 4.79 MB - ★★★★★ - 1 rating
Science Health & Fitness Medicine grace cancergrace gracecast lung cancer nsclc chemotherapy chemo radiation non Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: ASCO 2012 LC Highlights: Dr. Joel Neal on Anti-PD-1 Immunotherapy for Advanced NSCLC (audio)

Next Episode: ASCO 2012 LC Highlights: Dr. Joel Neal on the LUX-Lung 3 Trial of Afatinib vs. Chemo for EGFR Mutation-Positive Advanced NSCLC (audio)

Dr. Joel Neal reviews the favorable results with chemo combined with the novel targeted therapy selumetinib, a MEK inhibitor, in KRAS mutatino-positive patients with advanced non-small cell lung cancer (NSCLC).